Core Insights - Liquidia Corporation will present four posters at the Pulmonary Hypertension Professional Association (PHPN) Symposium from September 18 to 20, 2025, in Seattle, focusing on innovative therapies for rare cardiopulmonary diseases [1][2]. Group 1: Presentation Details - The live thematic poster session will showcase new safety and exploratory efficacy data for LIQ861 (YUTREPIA™) in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) from the ASCENT study [2]. - Three previously published posters will also be presented, covering YUTREPIA's effects on cardiac effort, quality of life, and patient device usage [2][4]. Group 2: Poster Abstracts - The first poster will discuss initial safety and exploratory efficacy data on LIQ861 in PH-ILD patients [4]. - The second poster will provide insights into changes in cardiac effort in PH-ILD patients from the ASCENT trial [4]. - The third poster will focus on quality of life in pulmonary arterial hypertension (PAH) patients receiving LIQ861 in the INSPIRE study [4]. - The fourth poster will address the robustness of LIQ861 in patient misuse scenarios [5]. Group 3: Product Information - YUTREPIA is an inhaled dry-powder formulation of treprostinil, designed for the treatment of PAH and PH-ILD, aimed at improving exercise ability [5]. - The product utilizes Liquidia's PRINT technology, which allows for precise and uniform drug particle development for enhanced lung deposition [5][6]. - Liquidia is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [6].

Core Viewpoint - Liquidia Corporation reported strong early commercial performance and clinical evidence for its newly approved product YUTREPIA, indicating significant market demand and potential for growth in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2][3][5] Company Highlights - The FDA approved YUTREPIA on May 23, 2025, and it was commercially launched in June 2025, with over 900 unique patient prescriptions and more than 550 patient starts recorded within 11 weeks post-launch [6][7] - The initial demand for YUTREPIA has exceeded expectations, with 75% of prescriptions converting to treatment starts in the first six weeks [7] - Liquidia has signed a lease for approximately 70,000 square feet of additional manufacturing space, targeted for occupancy in 2026, to support continued growth [7] - The company received $50 million under its financing agreement with Healthcare Royalty following the first commercial sale of YUTREPIA [7] Clinical Evidence - The ongoing ASCENT study has shown positive interim data, with median improvements in six-minute walk distance of 21.5 meters at Week 8 and 31.5 meters at Week 16, reinforcing YUTREPIA's tolerability and efficacy profile [4][8] - The study fully enrolled 54 patients, with no discontinuations due to drug-related adverse events, indicating a favorable safety profile [4][8] Financial Performance - As of June 30, 2025, Liquidia reported cash and cash equivalents of $173.4 million, a slight decrease from $176.5 million at the end of 2024 [9][27] - Product revenue for the second quarter of 2025 was $6.5 million, marking the first revenue recognition following YUTREPIA's approval [9][28] - Service revenue decreased to $2.3 million from $3.7 million in the same period last year, primarily due to unfavorable gross-to-net returns [10][28] - Research and development expenses decreased by 36% to $6.0 million, reflecting a shift towards commercialization activities [12][28] - Selling, general and administrative expenses increased by 95% to $38.8 million, driven by higher personnel costs and legal fees related to ongoing litigation [13][28] - The net loss for the second quarter was $41.6 million, or $0.49 per share, compared to a net loss of $28.7 million, or $0.38 per share, in the prior year [14][28]

Core Insights - Liquidia Corporation has announced the first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder, following FDA approval on May 23, 2025, for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1][6] - The company has moved quickly to promote YUTREPIA, with its sales force actively engaging in the market just over a week after FDA approval [2] - A recent court ruling denied United Therapeutics' request for a preliminary injunction against Liquidia, allowing for the full commercial launch of YUTREPIA [2] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases, particularly in pulmonary hypertension [9] - The company utilizes its proprietary PRINT technology to create drug formulations, including YUTREPIA, which is designed for enhanced lung deposition [5][9] - Liquidia is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [9] Product Information - YUTREPIA is an inhaled dry-powder formulation of treprostinil, delivered through a user-friendly device, aimed at providing a new therapeutic option for patients with PAH and PH-ILD [5][6] - The product was previously known as LIQ861 during investigational studies and has undergone clinical trials to establish its safety and efficacy [5] Disease Context - PAH is a rare, chronic disease affecting approximately 45,000 patients in the U.S., with no current cure, making symptom management and quality of life improvement critical [3] - PH-ILD encompasses a range of pulmonary diseases affecting over 60,000 patients in the U.S., with associated poor survival rates [4]